[Role of radiotherapy in the management of node-positive prostate cancer]

Abstract

Node-positive prostate cancer patients represent a small proportion of all prostate cancers for whom limited prospective information is available. Most retrospective or cohort data strongly suggest however that radiotherapy combined with androgen-depriving therapies is the preferable treatment in this setting. Only randomized clinical trials would be able to better define both radiotherapy (dose? volume? fractionation?) and androgen-depriving therapies (duration? role of novel androgen-depriving therapy?) modalities.

Keywords: Adénome de la prostate; Androgen depriving therapy; Cancer de la prostate métastatique; Hormonetherapy; Hormonothérapie; Irradiation; Metastatic prostate cancer; N1; Oligometastases; Oligométastases; Pelvis; Prostate adenocarcinoma; cN1; pN1.